
Valiant Organics Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- FY23 volume expected around 60,000-65,000 tons, up from ~50,000 tons (Page 14-15).
- Hydrogenation volumes (including PAP and OAP) to increase, with PAP ramping from 300 to 500 tons/month in H1 FY23 and targeted 1000 tons/month by end of FY23 (Pages 14, 18-19).
- Continuous process at PAP expected to improve margins and volumes further beyond 500 tons/month (Page 19).
- Sales guidance: FY23 standalone revenue target ~1200-1250 crores; FY24 target ~1400 crores (Page 18).
- EBITDA margin expected to improve to around 15% at 500 tons/month PAP volume and higher with continuous process (Page 19).
- Revenue growth guidance: 35-40% growth next year (FY23), followed by 15-20% growth in the subsequent year (Page 18).
- New products OAP and pharma intermediates expected to start contributing from Q2 FY23, supporting volume growth (Page 8).
See what Valiant Organics management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- No new long-term borrowings are planned for the near future.
- The company expects to fund its CAPEX internally without raising new debt.
- Some short-term loans for working capital may fluctuate, but no major increase in debt expected.
- Debt to equity ratio is currently comfortable at about 25%.
- Management aims to reduce short-term loans as working capital requirements normalize.
- No mention of any planned equity fundraising in the call.
See what Valiant Organics management said on order book — free account, 30 seconds.
Capex plans
Yes- For FY23, the planned CAPEX is around Rs. 60-70 crores.
- Major portion allocated for Ahmedabad plant redevelopment.
- Additional CAPEX for pharma intermediates expansion and moving PAP (para-aminophenol) production to continuous processing.
- The continuous process at PAP will require further CAPEX as part of scaling up production.
- The pharma intermediates project has incurred about Rs. 55 crores out of a Rs. 60 crore budget but is not yet commercialized.
- OAP (ortho-aminophenol) project, with a budget around Rs. 30 crores, is also in progress but not yet commercialized.
- Continuous process for PAP aims to increase production capacity beyond the current batch process limit of 500 tons/month.
- No major new large ticket investments are planned until stabilization of ongoing projects.
Track Valiant Organics — get its next earnings analysis in your feed
How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Valiant Organics rank in Chemicals & Petrochemicals?
Compare Valiant Organics against every Chemicals & Petrochemicals company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Valiant Organics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…